What Happened?

A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage plans. 

This change raises the revenue that insurance companies receive per patient from federal funds without increasing their costs. This is projected to improve profit margins for major providers like UnitedHealth and Humana.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Medical Devices & Supplies - Cardiology, Neurology, Vascular company Artivion (NYSE: AORT) jumped 3.6%. Is now the time to buy Artivion? Access our full analysis report here, it’s free.
• Generic Pharmaceuticals company ANI Pharmaceuticals (NASDAQ: ANIP) jumped 3.9%. Is now the time to buy ANI Pharmaceuticals? Access our full analysis report here, it’s free.
• Healthcare Technology for Providers company Privia Health (NASDAQ: PRVA) jumped 3.5%. Is now the time to buy Privia Health? Access our full analysis report here, it’s free.

Zooming In On ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals’s shares are not very volatile and have only had 7 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 8 months ago when the stock gained 18.4% on the news that the company reported second-quarter earnings and revenue that surpassed analyst estimates and raised its full-year financial guidance. 

The specialty pharmaceutical company announced quarterly net revenues of $211.4 million, a 53.1% year-over-year increase that beat analyst estimates of $191.5 million. Adjusted earnings per share came in at $1.80, also significantly higher than the consensus forecast of $1.42. Bolstering investor confidence, ANI Pharmaceuticals increased its 2025 forecast, now expecting full-year revenues between $818 million and $843 million and adjusted earnings per share from $6.98 to $7.35, both well above prior guidance.

ANI Pharmaceuticals is up 2.1% since the beginning of the year, but at $80.09 per share, it is still trading 18.9% below its 52-week high of $98.81 from September 2025. Investors who bought $1,000 worth of ANI Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $2,493.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.